Fusion Pharmaceuticals Inc

+0.15 (+3.19%)
Earnings Announcements

Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update

Published: 11/09/2021 12:41 GMT
Fusion Pharmaceuticals Inc (FUSN) - Q3 Loss per Share $0.45.
Qtrly Net Loss per Share $0.45.
Fpi-1434 Phase 1 Multi-dose Data Now Expected in 2h 2022.
Fpi-2059 Investigational New Drug Application (ind) on Track for First Half 2022.
Expects Cash, Cash Equivalents, Investments As of September 30, Will Enable Co to Fund Operations Through End of 2023.
As of September 30, 2021, Co Held Cash, Cash Equivalents and Investments of $238.2 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.46

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.49

More details on our Analysts Page.